



US009087145B2

(12) **United States Patent**  
**Ballou, Jr. et al.**

(10) **Patent No.:** **US 9,087,145 B2**  
(45) **Date of Patent:** **Jul. 21, 2015**

(54) **OPHTHALMIC DRUG DELIVERY**

(56) **References Cited**

(75) Inventors: **Bernard L. Ballou, Jr.**, Raleigh, NC (US); **Mark Packer**, Eugene, OR (US); **Russell John Mumper**, Chapel Hill, NC (US); **Tsontcho Inachulev**, San Mateo, CA (US)

(73) Assignee: **Eyenovia, Inc.**, Tampa, FL (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/184,446**

(22) Filed: **Jul. 15, 2011**

(65) **Prior Publication Data**

US 2012/0070467 A1 Mar. 22, 2012

#### **Related U.S. Application Data**

(60) Provisional application No. 61/400,864, filed on Jul. 15, 2010, provisional application No. 61/401,850, filed on Aug. 20, 2010, provisional application No. 61/401,920, filed on Aug. 20, 2010, provisional application No. 61/401,918, filed on Aug. 20, 2010, provisional application No. 61/401,848, filed on Aug. 20, 2010, provisional application No. 61/401,849, filed on Aug. 20, 2010, provisional application No. 61/462,576, filed on Feb. 4, 2011, provisional application No. 61/462,791, filed on Feb. 5, 2011, provisional application No. 61/463,280, filed on Feb. 15, 2011, provisional application No. 61/516,462, filed on Apr. 4, 2011, provisional application No. 61/516,496, filed on Apr. 4, 2011, provisional application No. 61/516,495, filed on Apr. 4, 2011, provisional application No. 61/516,694, filed on Apr. 6, 2011.

(51) **Int. Cl.**

**A61F 9/00** (2006.01)  
**A61P 27/06** (2006.01)  
**A61P 31/04** (2006.01)  
**A61M 11/00** (2006.01)  
**A61M 35/00** (2006.01)  
**A61K 31/5377** (2006.01)  
**A61K 31/7036** (2006.01)  
**A61K 9/00** (2006.01)  
**B05B 17/00** (2006.01)  
**G06F 19/00** (2011.01)

(52) **U.S. Cl.**

CPC ..... **G06F 19/3406** (2013.01); **A61F 9/00** (2013.01); **A61F 9/0008** (2013.01); **A61M 11/00** (2013.01); **G06F 19/3418** (2013.01); **A61M 2210/0612** (2013.01); **G06F 19/322** (2013.01); **G06F 19/3456** (2013.01); **G06F 19/3487** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61F 9/0008**; **A61M 2210/0612**  
See application file for complete search history.

#### **U.S. PATENT DOCUMENTS**

1,482,747 A	2/1924	Howe
1,988,637 A	1/1935	Tinkham
2,189,643 A	2/1940	Ward
2,200,008 A	5/1940	Nowak
2,249,608 A	7/1941	Greene
2,322,808 A	6/1943	Hothersall
2,552,857 A	5/1951	Knapp
2,595,317 A	5/1952	White
2,987,439 A	6/1961	Wittlinger
3,170,462 A	2/1965	Hall
3,187,757 A	6/1965	Jones et al.
3,237,809 A	3/1966	Daragan et al.
3,310,830 A	3/1967	Gattone
3,314,426 A	4/1967	Caroll
3,439,674 A	4/1969	Lelicoff
3,602,399 A	8/1971	Litman et al.
3,658,257 A	4/1972	Rood
3,709,235 A	1/1973	Washburn et al.
3,779,245 A	12/1973	Windsor
3,780,950 A	12/1973	Brennan
3,795,351 A	3/1974	Lehmann
3,812,854 A	5/1974	Michaels et al.
3,826,258 A	7/1974	Abraham
3,845,764 A	11/1974	Windsor
3,901,443 A	8/1975	Mitsui et al.
3,906,949 A	9/1975	Holland
3,913,575 A	10/1975	Windsor
3,934,585 A	1/1976	Maurice
4,002,168 A	1/1977	Petterson
4,012,798 A	3/1977	Liautaud
4,052,985 A	10/1977	Coleman et al.

(Continued)

#### **FOREIGN PATENT DOCUMENTS**

CA	2451835	1/2003
DE	196 16 300 A1	10/1997

(Continued)

#### **OTHER PUBLICATIONS**

Santvliet et al., Survey of Ophthalmology, Mar.-Apr. 2004, vol. 49, pp. 197-211.\*

(Continued)

*Primary Examiner* — Brian-Yong Kwon

*Assistant Examiner* — Mark V Stevens

(74) *Attorney, Agent, or Firm* — Polsinelli PC

(57) **ABSTRACT**

The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.

**38 Claims, No Drawings**

(56)

## References Cited

## U.S. PATENT DOCUMENTS

4,067,499	A	1/1978	Cohen	4,969,869	A	11/1990	Burgin et al.
4,098,431	A	7/1978	Palmer et al.	4,981,479	A	1/1991	Py
D249,709	S	9/1978	Trovinger	4,996,502	A	2/1991	Endo
4,119,096	A	10/1978	Drews	5,007,905	A	4/1991	Bauer
4,122,556	A	10/1978	Poler	5,019,037	A	5/1991	Wang et al.
4,131,115	A	12/1978	Peng	5,029,579	A	7/1991	Trammell
4,173,226	A	11/1979	Shell	5,030,214	A	7/1991	Spector
4,175,704	A	11/1979	Cohen	5,032,111	A	7/1991	Morris et al.
4,175,706	A	11/1979	Gerstmann	5,037,012	A	8/1991	Langford
4,264,837	A	4/1981	Gaboriaud	5,040,706	A	8/1991	Davis et al.
4,296,071	A	10/1981	Weiss et al.	5,047,009	A	9/1991	Morris et al.
4,319,155	A	3/1982	Nakai et al.	5,048,727	A	9/1991	Vlasich
4,323,530	A	4/1982	Voss et al.	5,053,000	A	10/1991	Booth et al.
4,338,936	A	7/1982	Nelson	5,054,477	A	10/1991	Terada et al.
4,356,528	A	10/1982	Coffee	5,064,420	A	11/1991	Clarke et al.
4,381,533	A	4/1983	Coffee	5,066,276	A	11/1991	Wang
4,388,343	A	6/1983	Voss et al.	5,069,204	A	12/1991	Smith et al.
4,390,542	A	6/1983	Schachar	5,069,675	A	12/1991	Menchel et al.
4,398,909	A	8/1983	Portnoff	5,085,651	A	2/1992	Py
4,465,234	A	8/1984	Maehara et al.	5,098,375	A	3/1992	Baier
4,471,890	A	9/1984	Dougherty	5,133,702	A	7/1992	Py
4,476,515	A	10/1984	Coffee	5,134,993	A	8/1992	van der Linden et al.
4,479,609	A	10/1984	Maeda et al.	5,139,496	A	8/1992	Hed
4,493,119	A	1/1985	Baumann	5,145,113	A	9/1992	Burwell et al.
4,543,096	A	9/1985	Keene	5,152,435	A	10/1992	Stand et al.
4,544,570	A	10/1985	Plunkett et al.	5,152,456	A	10/1992	Ross et al.
4,564,016	A	1/1986	Maurice et al.	5,163,929	A	11/1992	Py
4,580,721	A	4/1986	Coffee et al.	5,164,740	A	11/1992	Ivri
4,605,167	A	8/1986	Maehara	5,170,782	A	12/1992	Kocinski
4,605,398	A	8/1986	Herrick	5,171,306	A	12/1992	Vo
4,627,845	A	12/1986	DeMotte	5,176,856	A	1/1993	Takahashi et al.
4,641,384	A	2/1987	Landsberger et al.	5,193,745	A	3/1993	Holm
4,642,581	A	2/1987	Erickson	5,201,726	A	4/1993	Kirkham
4,658,290	A	4/1987	McKenna et al.	5,203,506	A	4/1993	Gross et al.
4,659,014	A	4/1987	Soth et al.	5,226,538	A	7/1993	Roselle
4,679,551	A	7/1987	Anthony	5,252,318	A	10/1993	Joshi et al.
4,685,906	A	8/1987	Murphy	5,259,385	A	11/1993	Miller et al.
4,701,167	A	10/1987	Chekan	5,261,601	A	11/1993	Ross et al.
4,702,418	A	10/1987	Carter et al.	5,265,288	A	11/1993	Allison
4,706,848	A	11/1987	D'Andrade	5,267,986	A	12/1993	Py
4,740,206	A	4/1988	Allander	5,276,867	A	1/1994	Kenley et al.
4,742,713	A	5/1988	Abe et al.	5,299,739	A	4/1994	Takahashi et al.
4,750,650	A	6/1988	Ling	5,316,159	A	5/1994	Douglas et al.
4,750,902	A	6/1988	Wuchinich et al.	5,318,014	A	6/1994	Carter
4,758,237	A	7/1988	Sacks	5,320,845	A	6/1994	Py
4,758,727	A	7/1988	Tomei et al.	5,354,032	A	10/1994	Sims et al.
4,759,755	A	7/1988	Hein et al.	5,364,405	A	11/1994	Zaleski
4,779,768	A	10/1988	St. Amand	5,368,582	A	11/1994	Bertera
4,784,652	A	11/1988	Wikström	5,401,259	A	3/1995	Py
4,790,479	A	12/1988	Matsumoto et al.	5,405,614	A	4/1995	D'Angelo et al.
4,792,334	A	12/1988	Py	5,431,663	A	7/1995	Carter
4,793,339	A	12/1988	Matsumoto et al.	5,435,282	A	7/1995	Haber et al.
4,796,807	A	1/1989	Bendig et al.	5,435,465	A	7/1995	El-Amin
4,798,599	A	1/1989	Thomas	5,462,586	A	10/1995	Sugiyama et al.
4,809,914	A	3/1989	Goncalves	5,485,828	A	1/1996	Hauser
4,815,661	A	3/1989	Anthony	5,496,411	A	3/1996	Candy
4,826,025	A	5/1989	Abiko et al.	5,499,751	A	3/1996	Meyer
4,850,534	A	7/1989	Takahashi et al.	D368,774	S	4/1996	Py
4,863,073	A	9/1989	Burt et al.	5,515,841	A	5/1996	Robertson et al.
4,863,443	A	9/1989	Hornung	5,518,179	A	5/1996	Humberstone et al.
4,863,457	A	9/1989	Lee	5,529,055	A	6/1996	Gueret
4,871,091	A	10/1989	Preziosi	D374,719	S	10/1996	Py
4,877,989	A	10/1989	Drews et al.	5,564,016	A	10/1996	Korenshtein
4,880,146	A	11/1989	Hudgins	5,584,823	A	12/1996	Valberg
4,881,283	A	11/1989	Liautaud	5,586,550	A	12/1996	Ivri et al.
4,886,189	A	12/1989	Vanderjagt	5,588,564	A	12/1996	Hutson et al.
4,896,832	A	1/1990	Howlett	5,607,410	A	3/1997	Branch
4,908,024	A	3/1990	Py	5,613,957	A	3/1997	Py
4,912,357	A	3/1990	Drews et al.	5,614,545	A	3/1997	Martin et al.
4,917,274	A	4/1990	Asa et al.	5,630,793	A *	5/1997	Rowe ..... 604/20
4,927,062	A	5/1990	Walsh	5,657,926	A	8/1997	Toda
4,927,115	A	5/1990	Bahroos et al.	5,665,079	A	9/1997	Stahl
4,946,452	A	8/1990	Py	5,685,869	A	11/1997	Py
4,952,212	A	8/1990	Booth et al.	5,687,874	A	11/1997	Omori et al.
4,961,885	A	10/1990	Avrahami et al.	5,707,636	A	1/1998	Rodriguez et al.
				5,724,021	A	3/1998	Perrone
				5,730,723	A	3/1998	Castellano et al.
				5,735,811	A	4/1998	Briskin
				5,740,947	A	4/1998	Flaig et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,746,728 A	5/1998	Py	6,651,650 B1	11/2003	Yamamoto et al.
5,758,637 A	6/1998	Ivri et al.	6,659,364 B1	12/2003	Humberstone et al.
5,803,106 A	9/1998	Cohen et al.	6,669,961 B2	12/2003	Kim et al.
5,807,357 A	9/1998	Kang	6,676,034 B2	1/2004	Tanaka et al.
5,823,428 A	10/1998	Humberstone et al.	6,679,436 B1	1/2004	Onishi et al.
5,838,350 A	11/1998	Newcombe et al.	6,684,681 B1	2/2004	Zombo
5,843,109 A	12/1998	Mehta et al.	6,684,879 B1	2/2004	Coffee et al.
5,855,322 A	1/1999	Py	6,719,770 B2	4/2004	Laufer et al.
5,881,956 A	3/1999	Cohen et al.	6,732,944 B2	5/2004	Litherland et al.
5,893,515 A	4/1999	Hahn et al.	6,736,904 B2	5/2004	Poniatowski et al.
5,894,841 A	4/1999	Voges	6,740,107 B2	5/2004	Loeb et al.
5,938,117 A	8/1999	Ivri	6,748,944 B1	6/2004	Della Vecchia et al.
D413,668 S	9/1999	Mannberg et al.	6,761,286 B2	7/2004	Py et al.
5,957,943 A	9/1999	Vaitekunas	6,789,741 B2	9/2004	Varanasi et al.
5,970,974 A	10/1999	Van Der Linden et al.	6,814,071 B2	11/2004	Klimowicz et al.
5,996,903 A	12/1999	Asai et al.	6,851,626 B2	2/2005	Patel et al.
5,997,518 A	12/1999	Laibovitz et al.	6,854,662 B2	2/2005	Chen
6,008,468 A	12/1999	Tanaka et al.	6,863,224 B2	3/2005	Terada et al.
6,011,062 A *	1/2000	Schneider et al. .... 514/530	6,877,642 B1	4/2005	Maddox et al.
6,027,450 A	2/2000	Brown	6,885,818 B2	4/2005	Goldstein
6,039,565 A	3/2000	Chou et al.	6,901,926 B2	6/2005	Yamamoto et al.
6,062,212 A	5/2000	Davison et al.	6,913,205 B2	7/2005	Cornet et al.
6,083,922 A	7/2000	Montgomery	6,921,020 B2	7/2005	Ivri
6,085,740 A	7/2000	Ivri et al.	6,926,208 B2	8/2005	Ivri
6,135,427 A	10/2000	Tsai	6,946,117 B1	9/2005	Schutt et al.
6,152,383 A	11/2000	Chen	6,964,647 B1	11/2005	Babaev
6,159,188 A	12/2000	Laibovitz et al.	6,969,165 B2	11/2005	Olsen
6,193,683 B1	2/2001	Ludin et al.	6,974,450 B2	12/2005	Weber et al.
6,203,759 B1	3/2001	Pelc et al.	6,976,279 B1	12/2005	Berke et al.
6,216,966 B1	4/2001	Prendergast et al.	6,976,969 B2	12/2005	Messerly
6,221,038 B1	4/2001	Briskin	6,978,945 B2	12/2005	Wong et al.
6,228,046 B1	5/2001	Briskin	7,017,573 B1	3/2006	Rasor et al.
6,235,024 B1	5/2001	Tu	7,032,590 B2	4/2006	Loeffler et al.
6,254,579 B1	7/2001	Cogger et al.	7,040,549 B2	5/2006	Ivri et al.
6,254,587 B1	7/2001	Christ et al.	7,066,398 B2	6/2006	Borland et al.
6,263,872 B1	7/2001	Schuster et al.	7,081,757 B2	7/2006	Unsworth et al.
6,273,342 B1	8/2001	Terada et al.	7,083,112 B2	8/2006	Ivri
6,296,626 B1	10/2001	Stein	7,104,463 B2	9/2006	Litherland et al.
6,318,361 B1	11/2001	Sosiak	7,108,197 B2	9/2006	Ivri
6,336,917 B1	1/2002	Berke	7,121,275 B2	10/2006	Noolandi et al.
6,341,732 B1	1/2002	Martin et al.	D533,658 S	12/2006	Collins, Jr. et al.
6,357,442 B1	3/2002	Casper et al.	7,153,315 B2	12/2006	Miller
6,357,671 B1	3/2002	Cewers	7,161,269 B2	1/2007	Kayama et al.
6,367,685 B1	4/2002	Jiang et al.	7,168,633 B2	1/2007	Wang et al.
6,394,363 B1	5/2002	Arnott et al.	D537,160 S	2/2007	Lowell
6,398,737 B2	6/2002	Moore et al.	7,174,888 B2	2/2007	Ivri et al.
6,398,766 B1	6/2002	Branch	7,192,129 B2	3/2007	Droege et al.
6,422,431 B2	7/2002	Pelc et al.	7,201,732 B2	4/2007	Anderson et al.
6,423,040 B1	7/2002	Benktzon et al.	7,204,820 B2	4/2007	Akahoshi
6,425,888 B1	7/2002	Embleton et al.	7,229,028 B2	6/2007	Chen et al.
6,427,682 B1	8/2002	Klimowicz et al.	7,234,460 B2	6/2007	Greenleaf et al.
6,442,423 B1	8/2002	Domb et al.	7,314,187 B2	1/2008	Hochrainer et al.
6,443,146 B1	9/2002	Voges	7,316,067 B2	1/2008	Blakey
6,467,476 B1	10/2002	Ivri et al.	7,331,339 B2	2/2008	Smith et al.
6,524,287 B1	2/2003	Cogger	7,357,133 B2	4/2008	Goodchild
6,526,976 B1	3/2003	Baran	7,472,701 B2	1/2009	Pfichner et al.
6,530,370 B1	3/2003	Heinonen	D597,206 S	7/2009	Collins, Jr. et al.
6,540,153 B1	4/2003	Ivri	7,574,787 B2	8/2009	Xu et al.
6,540,154 B1	4/2003	Ivri et al.	7,678,089 B2	3/2010	Py et al.
6,543,443 B1	4/2003	Klimowicz et al.	7,712,466 B2	5/2010	Addington et al.
6,546,927 B2	4/2003	Litherland et al.	7,819,115 B2	10/2010	Sexton et al.
6,550,472 B2	4/2003	Litherland et al.	7,883,031 B2	2/2011	Collins, Jr. et al.
6,554,201 B2	4/2003	Klimowicz et al.	8,012,136 B2	9/2011	Collins, Jr. et al.
6,554,801 B1	4/2003	Steward et al.	2001/0025190 A1	9/2001	Weber et al.
6,569,131 B1	5/2003	Michael et al.	2001/0049608 A1	12/2001	Hochman
6,569,387 B1	5/2003	Furner et al.	2001/0056258 A1	12/2001	Evans
6,601,581 B1	8/2003	Babaev	2002/0016576 A1	2/2002	Lee
6,610,033 B1	8/2003	Melanson et al.	2002/0039502 A1	4/2002	Matsumoto et al.
6,612,302 B1	9/2003	Rand	2002/0043262 A1	4/2002	Langford et al.
6,615,824 B2	9/2003	Power	2002/0073989 A1	6/2002	Hadimioglu
6,619,562 B2	9/2003	Hamaguchi et al.	2002/0074362 A1	6/2002	Py et al.
6,622,720 B2	9/2003	Hadimioglu	2002/0107492 A1	8/2002	Brach et al.
6,629,646 B1	10/2003	Ivri	2002/0121285 A1	9/2002	Poniatowski et al.
6,640,804 B2	11/2003	Ivri et al.	2002/0124843 A1	9/2002	Skiba et al.
6,650,935 B1	11/2003	Watmough	2002/0161344 A1	10/2002	Peclat et al.
			2003/0032930 A1	2/2003	Branch
			2003/0078551 A1	4/2003	Hochrainer et al.
			2003/0114901 A1	6/2003	Loeb et al.
			2003/0144594 A1	7/2003	Gellman

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2003/0185892	A1	10/2003	Bell et al.
2003/0192532	A1	10/2003	Hopkins
2004/0010239	A1	1/2004	Hochrainer et al.
2004/0039355	A1	2/2004	Gonzalez et al.
2004/0045547	A1	3/2004	Yamamoto et al.
2004/0050953	A1	3/2004	Terada et al.
2004/0082884	A1	4/2004	Pal et al.
2004/0164099	A1	8/2004	Diestelhorst et al.
2004/0176757	A1	9/2004	Sinelnikov et al.
2004/0186384	A1	9/2004	Babaev
2004/0204674	A1	10/2004	Anderson et al.
2004/0215157	A1*	10/2004	Peclat et al. .... 604/294
2004/0220537	A1	11/2004	Embleton et al.
2004/0256487	A1	12/2004	Collins, Jr. et al.
2005/0001981	A1	1/2005	Anderson et al.
2005/0029307	A1	2/2005	Py et al.
2005/0077315	A1	4/2005	Pavlu et al.
2005/0077392	A1	4/2005	Geser et al.
2005/0089545	A1	4/2005	Kuwano et al.
2005/0195598	A1	9/2005	Dancs et al.
2005/0199236	A1	9/2005	Fink et al.
2005/0240162	A1	10/2005	Chen et al.
2005/0244339	A1	11/2005	Jauernig et al.
2005/0261641	A1	11/2005	Warchol et al.
2005/0263608	A1	12/2005	Ivri
2005/0275310	A1	12/2005	Ripoll
2005/0279350	A1	12/2005	Rasor et al.
2006/0024374	A1	2/2006	Gasco et al.
2006/0057216	A1	3/2006	Salamone et al.
2006/0174869	A1	8/2006	Gumaste et al.
2006/0196518	A1	9/2006	Hon
2006/0201501	A1	9/2006	Morrison et al.
2006/0209129	A1	9/2006	Onozawa
2006/0213503	A1	9/2006	Borgschulte et al.
2006/0258993	A1	11/2006	Hochrainer et al.
2007/0023547	A1	2/2007	Borland et al.
2007/0044792	A1	3/2007	Ivri
2007/0113841	A1	5/2007	Fuchs
2007/0119968	A1	5/2007	Collins, Jr. et al.
2007/0119969	A1	5/2007	Collins, Jr. et al.
2007/0211212	A1	9/2007	Bennwik
2008/0017189	A1	1/2008	Ruckdeschel et al.
2008/0097359	A1	4/2008	Hochrainer et al.
2008/0142624	A1	6/2008	Ivri et al.
2008/0164339	A1	7/2008	Duru
2008/0233053	A1	9/2008	Gross et al.
2008/0299049	A1	12/2008	Stangl
2008/0303850	A1	12/2008	Shin et al.
2008/0308096	A1	12/2008	Borgschulte et al.
2009/0025713	A1	1/2009	Keller et al.
2009/0114742	A1	5/2009	Collins, Jr.
2009/0149829	A1	6/2009	Collins, Jr.
2009/0192443	A1	7/2009	Collins, Jr. et al.
2009/0212133	A1	8/2009	Collins, Jr. et al.
2010/0044460	A1	2/2010	Sauzade
2010/0211408	A1	8/2010	Park et al.
2010/0222752	A1	9/2010	Collins, Jr.
2010/0283601	A1	11/2010	Tai et al.

## FOREIGN PATENT DOCUMENTS

DE	19616300	A1	10/1997
DE	199 34 582	A1	1/2001
EP	0 011 269	A1	5/1980
EP	0 150 571	A1	8/1985
EP	0 224 352	A1	6/1987
EP	0 389 665	A1	10/1990
EP	0 590 165	A1	4/1994
EP	0 823 246	A2	2/1996
EP	0 933 138	A2	8/1999
EP	1 493 410	A2	1/2005
EP	1493410	A2	1/2005
FR	1 271 341		7/1961
GB	558866		7/1942

GB	1 569 707		7/1980
JP	8-52193		2/1996
JP	U3104861		4/2004
TW	1293898		7/1994
WO	WO 85/00761	A1	2/1985
WO	WO 91/12687	A1	8/1991
WO	WO 91/14468	A1	10/1991
WO	WO 94/13305	A1	6/1994
WO	WO 94/23788	A1	10/1994
WO	WO 95/26236		10/1995
WO	WO 96/06581		3/1996
WO	WO 97/05960	A1	2/1997
WO	WO 97/12687	A1	4/1997
WO	WO 97/23177		7/1997
WO	WO 98/19383	A1	5/1998
WO	WO 99/17888	A1	4/1999
WO	WO 00/18455	A1	4/2000
WO	WO 00/66277	A1	11/2000
WO	WO 01/03645	A2	1/2001
WO	WO 01/19437	A1	3/2001
WO	WO 01/58236	A2	8/2001
WO	WO 01/85245	A1	11/2001
WO	WO 02/28545	A1	4/2002
WO	WO 02/055131	A2	7/2002
WO	02/062488	A1	8/2002
WO	WO 02/062488	A1	8/2002
WO	WO 02/072169	A2	9/2002
WO	WO 03/002045	A1	1/2003
WO	WO 03/002265	A1	1/2003
WO	WO 03/026556	A2	4/2003
WO	2004/028420	A1	4/2004
WO	WO 2004/028420	A1	4/2004
WO	WO 2004/050065	A1	6/2004
WO	WO 2004/103478	A1	12/2004
WO	WO 2004/105864	A1	12/2004
WO	WO 2006/006963	A2	1/2006
WO	WO 2006/082588	A2	8/2006
WO	WO 03/097139	A1	11/2006
WO	WO 2008/015394	A1	2/2008
WO	2009/148345	A2	12/2009
WO	WO 2009/148345	A2	12/2009
WO	WO 2012/009702	A1	1/2012
WO	WO 2012/009706	A1	1/2012

## OTHER PUBLICATIONS

Brown et al., *Journal of the Society of Cosmetic Chemists*, 1965, vol. 16, pp. 369-393.\*

"Alcon®: Sharing One Vision," 2009 Annual Report, 46 pages (2009).

Conover (Ed.), "View into the Future of Ophthalmology Treatments," *Healthcare Observer*, 1(8):2-37 (2009).

Dhand, "Nebulizers That Use a Vibrating Mesh or Plate with Multiple Apertures to Generate Aerosol," *Respir Care*, 47(12):1406-1418 (2002).

Donnelly et al., "Using ultrasonic atomization to produce an aerosol of micron-scale particles," *Review of Scientific Instruments*, 76:113301-1-113301-10 (2005).

Durnam et al., "Gold-Chlorine and Gold-Bromine Equilibria in Fused Salts," *The Journal of Physical Chemistry*, 68(4):847-850 (1964).

Galambos et al., "Drop ejection utilizing sideways actuation of a MEMS piston," *Sensors and Actuators A*, 141:182-191 (2008).

Hinds, *Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles*, pp. 42-71, 111-119, & 294-301 (1999).

Instruction Manual for Omron® Model NE-U03V MicroAir® Nebulizer, 20 pages (No date).

International Search Report mailed Dec. 12, 2011, in International Application No. PCT/US2011/044291.

International Search Report mailed Dec. 13, 2011, in International Application No. PCT/US2011/044286.

Product Description for Xalatan®: latanoprost ophthalmic solution, Pfizer Manufacturing, Belgium, NV, 8 pages (2009).

Quigley, "Improving Eye Drop Treatment for Glaucoma through Better Adherence," *Optometry and Vision Science*, 85(6):374-375 (2008).

(56)

**References Cited**

OTHER PUBLICATIONS

Ranade et al., "Chapter seven: Intranasal and ocular drug delivery," *Drug Delivery Systems: Second Edition*, CLC Press, 39 pages (2004).  
 Rosen et al., "Printing High Viscosity Fluids Using Ultrasonic Drop-let Generation," The George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, pp. 239-253 (2008).  
 Shidhaye et al., "Novel drug delivery devices," *Pharma Times*, 38(7):24-27 (2006).

Tamilvanan et al., "The potential of lipid emulsion for ocular delivery of lipophilic drugs," *European Journal of Pharmaceutics and Biopharmaceutics*, 58:357-368 (2004).

Xia et al., "A potential application of a piezoelectric atomiser for ophthalmic drug delivery," *BOB*, 4(1):9-17 (2007).

Yee et al., "Trends in Glaucoma Treatment," EyeWorld Educational Symposium, San Francisco, 8 pages (2006).

Yuan et al., "MEMS-based piezoelectric array microjet," *Microelectronic Engineering*, 66:767-772 (2003).

\* cited by examiner

**OPHTHALMIC DRUG DELIVERY****RELATED APPLICATIONS**

The present application claims the benefit of the filing date of U.S. Provisional Application No. 61/400,864, filed Jul. 15, 2010, U.S. Provisional Application No. 61/401,850, filed Aug. 20, 2010, U.S. Provisional Application No. 61/401,920, filed Aug. 20, 2010, U.S. Provisional Application No. 61/401,918, filed Aug. 20, 2010, U.S. Provisional Application No. 61/401,848, filed Aug. 20, 2010, U.S. Provisional Application No. 61/401,849, filed Aug. 20, 2010, U.S. Provisional Application No. 61/462,576, filed Feb. 4, 2011, U.S. Provisional Application No. 61/462,791, filed Feb. 5, 2011, U.S. Provisional Application No. 61/463,280, filed Feb. 15, 2011, U.S. Provisional Application No. 61/516,462, filed Apr. 4, 2011, U.S. Provisional Application No. 61/516,496, filed Apr. 4, 2011, U.S. Provisional Application No. 61/516,495, filed Apr. 4, 2011, and U.S. Provisional Application No. 61/516,694, filed Apr. 6, 2011, the entire contents of each of which is specifically hereby incorporated by reference for all purposes. The present application is also related to U.S. Provisional Application No. 61/396,531, filed May 28, 2010, the entire contents of which is specifically hereby incorporated by reference for all purposes.

**FIELD OF THE INVENTION**

The present invention relates to devices for the generation of ejected droplets, methods of administration and uses thereof, and medicament compositions formulated therefor.

**BACKGROUND OF THE INVENTION**

A typical medical droplet as dispensed by an eye dropper bottle can vary, depending on the viscosity and surface tension of the fluid. In order to control the amount of active ingredient that is administered in a single droplet, the concentration of the active ingredient is adjusted by volume. Once the concentration is defined, a correct dosage may require one drop or more. However, since the human eye can typically retain only 7  $\mu$ l of fluid at a time, even a single medical droplet can result in overflow and loss of part of the medication from the eye. Multiple drop dosage often compounds the problem of medication retention in the eye. Subjects will typically administer all droplets required for a dosage in one sitting, which exacerbates the problem and can result in 50 to 90% of the medication overflowing and leaking out of the eye.

Another further problem is that a single droplet of the defined concentration marks the lower limit of a dose and, as such, the amount of active ingredient that can be administered at the defined concentration. For example, pediatric application where lower doses are often advisable are an illustration of where the size/dose of a droplet can be problematic.

Given the above and other limitations of current ophthalmic delivery, a need exists for an efficient delivery system for solutions to the eye, including solutions containing medicaments.

**SUMMARY OF THE INVENTION**

To address such needs and others, provided herein are stable medicament compositions and uses thereof.

One embodiment provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the

medicament, where said droplets have an average drop size of between about 15 microns and about 100 microns in diameters and an average ejecting velocity of between about 0.5 m/s to about 20 m/s; and (b) delivering the medicament to the eye, where between about 80% to about 100% of the ejected mass of the droplets are deposited on the eye.

Another embodiment provides a method of delivering a medicament solution to a subject in need thereof by controlling droplet size and droplet deposit parameters of the medicament solution, the method comprising: (a) determining desired dosage of the medicament solution for the subject in need thereof; and (b) providing the desired dosage in a single application by determining the droplet size and deposit parameters.

Yet another embodiment provides a method for providing a solution to the eye, the method comprising: (a) providing droplets containing the medicament, having an average droplet size of between about 15 microns and about 100 microns in diameter and an average initial ejecting velocity of between about 0.5 m/s to about 20 m/s; and (b) delivering the medicament to the eye, where between about 80% to about 100% of the ejected mass of the droplets are deposited on the eye.

These and other aspects of the invention will become apparent to one of skill in the art.

**DETAILED DESCRIPTION OF THE INVENTION****A. Methods of Generating Ejected Droplets**

The present invention provides an effective approach to undertake dosing strategies. Dosing strategies also will incorporate various approaches to initiating treatment, stopping treatment, switching treatment and responding to different subject states.

Examples of dosing modes or strategies include night time administration, administration before waking, increased administration one week a month, three times a day, continuous dosing, bolus dosing, taper dosing, need-based dosing, and feedback dosing by the physician, provider, subject or family. The clinical scenarios where these can be employed include chronic disease, disease exacerbation, need for suppression treatment, need for recurrence treatment, or state of treatment like medicament tolerance.

**B. Methods of Delivery and Treatment**

Provided is a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.

Devices capable of providing and delivering a fluid such as ophthalmic fluid to the eye are provided. In certain aspects, ejection devices include an ejection assembly which generates or provides a controllable stream of droplets of fluid. Fluids include, without limitation, suspensions and emulsions which have viscosity in a range capable of droplet formation using an ejector mechanism. As explained in further detail herein, in accordance with certain aspects of the present disclosure, the actuator mechanism may form a directed stream of droplets, which may be directed toward a target. The droplets will be formed in distribution of sizes, each distribution having an average droplet size. The average droplet size may be in the range of about 15 microns to about 100 microns, about 20 microns to about 100 microns, greater than 20 microns to about 100 microns, about 20 microns to about 80 microns, about 25 microns to about 75 microns, about 30 microns to about 60 microns, about 35 microns to

about 55 microns, etc. However, the average droplet size may be as large as 2500 microns, depending on the intended application. Further, the droplets may have an average initial ejecting velocity of about 0.5 m/s to about 20 m/s, e.g., about 1 m/s to about 10 m/s, about 1 m/s to about 5 m/s, about 1 m/s to about 4 m/s, about 2 m/s, etc. As used herein, the ejecting size and the ejecting initial velocity are the size and velocity of the droplets when the droplets leave the ejector plate. The stream of droplets directed at a target will result in deposition of a percentage of the mass of the droplets including their composition onto the desired location.

The disclosed technology will eject droplets without substantial evaporation, entrainment of air, or deflection off the eye surface, which facilitates consistent dosing. Average ejecting droplet size and average initial ejecting velocity are dependent on factors including fluid viscosity, surface tension, ejector plate properties, geometry, and dimensions, as well as operating parameters of the piezoelectric actuator including its drive frequency. In some implementations, about 60% to about 100%, about 65% to about 100%, about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, etc., of the ejected mass of droplets are deposited on the surface of the eye, such deposition being repeatable independent of operating and use conditions. The direction of flow of the stream of droplets may be horizontal, or any direction a user chooses to aim the actuation mechanism during use.

Droplet performance is generally related to particle diameter. Without intending to be limited, ejected droplets are slowed to a stop by air drag (i.e., stopping distance of the ejected droplets). Ejected droplets also fall vertically due to gravity. After a short acceleration time, the droplets reach terminal velocity where the drag force equals the force of gravity. The ejected droplets may carry air along with them, which creates an entrained airstream, which aids to then carry the ejected droplets beyond the calculated stopping distance. However, increased levels of entrained air may cause the ejected droplets to flow across an impact surface (e.g., an eye surface) because the entrained airflow must turn 90 degrees at such a surface. Small, ejected droplets (e.g., droplets having an average diameter less than about 17 microns, less than about 15 microns, etc.) are carried along the surface of the eye by the airstream and may not impact the surface. Contrasted to this, larger ejected droplets create less entrained air than an equivalent mass of smaller droplets, and have enough momentum to impact the surface. The ejected droplet stopping distance is a measure of this effect.

Also provided is a method of delivering a medicament solution to a subject in need thereof by controlling droplet size and deposit parameters of the medicament solution, the method comprising: (a) determining desired dosage of the medicament solution for the subject in need thereof; and (b) providing the desired dosage in a single application or multiple applications by determining the droplet size and deposit parameters.

Many factors, including those described herein, can influence the desired dosage. Once the desired dosage is determined, and also if desired frequency, such doses can be delivered. Frequency of dosing can vary by number of times, periodicity or both.

Also provided is a method for providing a solution to the eye, the method comprising: (a) providing droplets containing the solution, where the droplets have an average drop size in diameter and an average initial ejecting velocity; and (b) delivering the solution to the eye, where between about 80% to about 100% of the ejected mass of the droplets are deposited on the eye.

Further provided is a method of treating eye condition disorders, including glaucoma, infection or other eye indications, and related discomforts or other need in a subject in need thereof, the method comprising: (a) providing droplets containing said medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.

Further provided is a method of providing a reduced dosage form of a medicament to an eye comprising: (a) providing droplets containing the medicament, where the droplets have an average drop size and an average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a specified deposited mass of the droplets. In this or other aspects, the droplets can provide a total volume of less than 30  $\mu$ l, 20  $\mu$ l, 15  $\mu$ l, 10  $\mu$ l, 5  $\mu$ l or 2  $\mu$ l to eye.

#### C. Ejector Device

Exemplary ejector devices capable of generating droplets of the type described herein are provided in U.S. Patent Publication No. 2012/0143152, filed concurrently herewith, entitled "Drop-Generating Device", herein incorporated by reference in its entirety. In one aspect of one such device an ejector plate is coupled to an actuator. The manner and location of attachment of the actuator to the plate affects the operation of the ejection assembly and the creation of the droplet stream with the option of the actuator being a piezoelectric actuator.

As described in U.S. Patent Publication No. 2012/0143152, again herein incorporated by reference in its entirety, the ejector device may generally be an ejector device for delivering a fluid to an eye of a subject. For instance, the ejector device may comprise: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; and an ejector mechanism configured to eject a stream of droplets to the eye of a subject upon activation of the device by a user. The ejected stream of droplets may have an average ejected droplet diameter greater than 15 microns and a low entrained airflow such that the ejected stream of droplets is deposited on the eye of the subject during use. In certain embodiments, the ejector device includes a piezoelectric ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir and including a plurality of openings formed through its thickness, and a piezoelectric actuator coupled to a second surface of the ejector plate, the piezoelectric actuator operable to oscillate the ejector plate at a frequency and generate the ejected stream of droplets.

#### D. Medicament and Other Compositions

Any medicament showing a desired ophthalmic activity may be administered. In an aspect, the medicament is available by prescription. In another aspect, the medicament is available over-the-counter. In an aspect, the medicament is or comprises a biologic agent. In an aspect, the biologic agent is selected from the group consisting of a full-length antibody, an active fragment of a full-length antibody, a peptide, a pegylated peptide, and an enzymatic ingredient. In another aspect, the biologic ingredient is selected from the group consisting of bevacizumab, ranibizumab, FV fragments, bi-specific antibodies, fusion molecules, pegaptanib, plasmin and microplasmin. In a further aspect, the biologic agent is selected from the group consisting of ranibizumab antibody FAB (including Lucentis<sup>TM</sup>), VEGF Trap fusion molecule (including VEGF Trap-Eye<sup>TM</sup>), microplasmin enzyme (including Ocriplasmin<sup>TM</sup>), macugen pegylated polypeptide (including Pegaptanib<sup>TM</sup>), and bevacizumab (including Avastin<sup>TM</sup>).

In another aspect, a medicament to be administered is or comprises a small molecule. In an aspect, the medicament to be administered comprises a medicament selected from the group consisting of cyclosporine, neomycin, biomimidine, and aminoglycoside antibiotics, including, for example, tobramycin and gentamycin.

In various aspects, a solution may have different salinity. Salinity may be measured using a hydrometer. In various aspects, salinity may range from 0%, or a pure aqueous solution, to 2.5%. In other aspects, salinity may range from about 0.1% to about 1%, from about 0.5% to about 1%, from about 0.7% to about 1%, from about 0.8% to about 1%. In further aspects, salinity of a medicament may be about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, or about 1.5%. In other aspects, salinity may be less than about 1.5%, less than about 1%, less than about 0.5% or less than about 0.2%. In an aspect, the solution is isotonic with the site of delivery. For example, in various aspects, the medicament may be isotonic with human tears, blood, or eye tissue.

In an aspect, the medicament to be delivered comprises a medicament selected from the group consisting of carboxymethylcellulose sodium, tetrahydrozoline HCl, pheniramine maleate, ketotifen fumarate, oxymetazoline HCl, naphazoline HCl, pheniramine maleate, moxifloxacin hydrochloride, bromfenac, proparacaine hydrochloride, difluprednate, gatifloxacin, travoprost, bepotastine besilate, gatifloxacin, loteprednol etabonate, timolol ophthalmic, olopatadine hydrochloride, phenylephrine hydrochloride, levofloxacin, ketorolac tromethamine, letanoprost, bimatoprost and BAK free latanoprost. In another aspect, the medicament is selected from the group consisting of Refresh Tears™, Visine Advanced Relief™, Naphcon A™, Sensitive Eyes™, Renu™, Opti-Free™ rewetting drops, Visine A.C.™, Hypo Tears™, Alaway™, Visine L.R.™, Visine™ original, Rohto Cool™, Soothe XP™, Zaditor™, Bausch & Lomb Advanced Eye Relief Redness™, Visine A™, Opcon-A™, Walgreens artificial tears, Visine™ dry eye relief, Advanced Eye Relief Dry Eye™, Opti-free Replenish™, Clear Eyes™ redness relief, Vigamox™, Bromday™, Durezol™, Zymar™, Travatan Z™, Tropicamide™, Bepreve™, Zymar™, Lotemax™, Istalol™, Pataday™, AK-Dilate™, Toradol™, Xalatan™, and Lumigan™.

In another aspect, the medicament to be delivered comprises a medicament selected from the group consisting of fluorosilicone acrylate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, tetrahydrozoline HCl, carboxymethylcellulose sodium, propylene glycol, hypromellose, zinc sulfate, dorzolamide HCl timolol maleate, azithromycin, brimonidine tartrate, nepafenac, brinzolamide, besifloxacin, dorzolamide HCl, prednisone acetate, loteprednol etabonate, tobramycin/dexamethasone, and cyclosporine. In a further aspect, the medicament is selected from the group consisting of Tears Naturale II™, Optimum NWN™, Thera Tears™, Systane Ultra™, GenTear™, Systane Lubricant Eye Drops™, Blink™ tears, Visine Max Redness Relief™, Refresh Optive™, Muro 128™, Systane Balance™, Rohto Hydra™, Rohto Ice™, Walgreens sterile artificial tears, Rohto Arctic™, Clear Eyes™ natural tears lubricant, Similasan™ pink eye relief, Similasan™ allergy eye relief, Cosopt™, AzaSite™ Alphagan P™, Nevanac™, Azopt™, Besivance™ Trusopt™, Alrex™, and Restasis™.

In an aspect, an ophthalmic medicament to be delivered is used to treat glaucoma. In an aspect, a glaucoma medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzola-

midate HCl, and BAK free latanoprost. In a further aspect, a medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, and BAK free latanoprost. In another aspect, a medicament is selected from the group consisting of dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, and dorzolamide HCl. In an aspect, a glaucoma medicament is selected from the group consisting of Travatan™, Istalol™, Xalatan™, Lumigan™, Cosopt™, Alphagan P™, Azopt™, and Trusopt™. In another aspect, a medicament is selected from the group consisting of Travatan™, Istalol™, Xalatan™, and Lumigan™. In a further aspect, a medicament is selected from the group consisting of Cosopt™, Alphagan P™, Azopt™, and Dorzolamide HCl™.

In an aspect, the concentration of an active ingredient in a medicament is measured as a percentage of the active ingredient in solution. In an aspect, the concentration of active ingredient ranges from about 0.0001% to about 5%. In another aspect, the concentration of active ingredient in a medicament ranges from about 0.0005% to about 1%. In other aspects, the concentration of active ingredient ranges from about 0.0005% to about 0.0001%, from about 0.0001% to about 0.001%, or from about 0.0005% to about 0.001%. In other aspects, the concentration of active ingredient ranges from about 0.005% to about 0.001% or from about 0.001% to about 0.01%. In another aspect, the concentration of active ingredient ranges from about 0.001% to about 0.5%. In various other aspects, the concentration of active ingredient is selected from the group consisting of about 0.0001%, about 0.0005%, about 0.001%, about 0.0025%, about 0.005%, about 0.01%, about 0.025%, about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.75%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 4%, and about 5% measured as a percentage of the solution. However, given the lower dosing amounts afforded by the methods of the present disclosure, higher concentrations may be used depending on the intended use. For examples, about 10%, about 20%, about 25%, of the active ingredient in the medicament, measured as a percentage of the solution, may be utilized.

In an aspect, the medicament comprises a medicament selected from the group consisting of between about 0.02% and about 0.03% carboxymethylcellulose sodium, between about 0.4% and about 0.6% carboxymethylcellulose sodium, between about 0.04% and about 0.06% tetrahydrozoline HCl, between about 0.04% and about 0.06% tetrahydrozoline HCl, between about 0.24% and about 0.36% pheniramine maleate, between about 0.02% and about 0.03% ketotifen fumarate, between about 0.028% and about 0.042% ketotifen fumarate, between about 0.02% and about 0.03% oxymetazoline HCl, between about 0.0096% and about 0.0144% naphazoline HCl, between about 0.024% and about 0.036% naphazoline HCl, between about 0.24% and 0.36% pheniramine maleate, between about 0.4% and about 0.6% moxifloxacin hydrochloride, between about 0.072% and about 0.108% bromfenac, between about 0.4% and about 0.6% proparacaine hydrochloride, between about 0.04% and about 0.06% difluprednate, between about 0.4% and about 0.6% gatifloxacin, between about 0.0032% and about 0.0048% travoprost, between about 1.2% and about 1.8% bepotastine besilate, between about 0.24% and about 0.36% gatifloxacin, between about 0.4% and about 0.6% loteprednol etabonate, between about 0.4% and about 0.6% timolol ophthalmic, between about 0.16% and about 0.24% olopatadine hydrochloride, between about 2% and about 3% phenylephrine hydrochloride, between about 0.4% and about 0.6% levofloxacin, between about 0.32% and about 0.48% ketorolac



tromethamine, between about 0.004% and about 0.006% letanoprost, and between about 0.024% and about 0.036% bimatoprost.

In an aspect, the medicament comprises a medicament selected from the group consisting of 0.025% carboxymethylcellulose sodium, 0.5% carboxymethylcellulose sodium, 0.05% tetrahydrozoline HCl, 0.5%, tetrahydrozoline HCl, 0.3% pheniramine maleate, 0.025% ketotifen fumarate, 0.035% ketotifen fumarate, 0.025% oxymetazoline HCl, 0.012% naphazoline HCl, 0.03% naphazoline HCl, 0.3% pheniramine maleate, 0.5% moxifloxacin hydrochloride, 0.09% bromfenac, 0.5% proparacaine hydrochloride, 0.05% difluprednate, 0.5% gatifloxacin, 0.004% travoprost, 1.5% bepotastine besilate, 0.3% gatifloxacin, 0.5% loteprednol etabonate, 0.5% timolol ophthalmic, 0.2% olopatadine hydrochloride, 2.5% phenylephrine hydrochloride, 0.5% levofloxacin, 0.4% ketorolac tromethamine, 0.005% letanoprost, and 0.03% bimatoprost.

In another aspect, the medicament to be delivered comprises a medicament selected from the group consisting of between about 0.02% and about 0.3% sodium carboxymethylcellulose, between about 0.04% and about 0.06% tetrahydrozoline HCl, between about 0.4% and about 0.6% carboxymethylcellulose sodium, between about 0.48% and about 0.72% propylene glycol, between about 0.24% and about 0.36% hypromellose, between about 0.2% and about 0.3% zinc sulfate, between about 0.8% and about 1.2% azithromycin, between about 0.08% and about 0.12% brimonidine tartrate, between about 0.08% and about 0.12% nepafenac, between about 0.8% and about 1.2% brinzolamide, between about 0.48% and about 0.72% besifloxacin, between about 1.6% and about 2.4% dorzolamide HCl, between about 0.8% and about 1.2% prenisonone acetate, between about 0.16% and about 0.24% loteprednol etabonate, between about 0.32% and about 0.48% tobramycin/dexamethasone, and between about 0.04% and about 0.06% cyclosporine.

In another aspect, the medicament to be delivered comprises a medicament selected from the group consisting of 0.025% sodium carboxymethylcellulose, 0.05% tetrahydrozoline HCl, 0.5% carboxymethylcellulose sodium, 0.6% propylene glycol, 0.3% hypromellose, 0.25% zinc sulfate, 1% azithromycin, 0.1% brimonidine tartrate, 0.1% nepafenac, 1% brinzolamide, 0.6% besifloxacin, 2% dorzolamide HCl, 1% prenisonone acetate, 0.2% loteprednol etabonate, 0.4% tobramycin/dexamethasone, and 0.05% cyclosporine.

In an aspect, the medicament to be administered is not water-soluble. In another aspect, the medicament to be administered is poorly water-soluble. In a preferred aspect, the medicament is water-soluble, highly water-soluble, or very highly water-soluble. In an aspect, poorly water soluble is less than 10 ug/mL. In other aspects, water soluble is 10 to 60 ug/mL, highly water soluble is greater than 60 to 120 ug/mL, and very highly water soluble is greater than 120 ug/mL.

In another aspect, the medicament to be administered is formulated in an emulsion or a suspension. In an aspect, the medicament to be delivered comprises difluprednate or loteprednol etabonate. In an aspect, the medicament is Durzol™ or Lotemax™.

As generally understood by those skilled in the art, the listing of an active agent includes medicamentally acceptable salts, esters, and acids thereof.

In an aspect, a medicament to be delivered comprises a preservative or other additive acceptable for use in the eye. In an aspect, a medicament comprises 20% or less of a preservative or other additive, or 15% or less, 12% or less, 10% or

less, 8% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, 0.1% or less of a preservative or other additive.

In another aspect, the medicament to be delivered comprises a polymeric ingredient. In an aspect, the medicament comprises an additive selected from the group consisting of glycerin, castor oil, carbomer, polyethylene glycol, and polysorbate 80. In an aspect, the concentration of polymer is measured as a percentage of the total solution by weight. In various aspects, the medicament comprises 10% or less of a polymer, 5% or less of a polymer, 4% or less of a polymer, 3% or less of a polymer, 2% or less of a polymer, 1.5% or less of a polymer, 1% or less of a polymer, 0.5% or less of a polymer, 0.4% or less of a polymer, 0.3% or less of a polymer, 0.2% or less of a polymer, 0.1% or less of a polymer, 0.05% or less of a polymer, or no detectable polymer. In various aspects, the medicament comprises 10% or less glycerin, 5% or less glycerin, 4% or less glycerin, 3% or less glycerin, 2% or less glycerin, 1.5% or less glycerin, 1% or less glycerin, 0.5% or less glycerin, 0.4% or less glycerin, 0.3% or less glycerin, 0.2% or less glycerin, 0.1% or less glycerin, 0.05% or less glycerin, or no glycerin.

In various aspects, the medicament may have different tonicity. Tonicity may be measured using a hydrometer. In various aspects, tonicity may range from 0%, or a pure aqueous solution, to 2.5%. In other aspects, tonicity may range from 0.1% to 1%, from 0.5% to 1%, from 0.7% to 1%, from 0.8% to 1%. In further aspects, tonicity of a medicament may be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%. In an aspect, the medicament is isotonic with the site of delivery. For example, in various aspects, the medicament may be isotonic with human tears, blood, or eye tissue. It is contemplated that a solution with no active ingredient can be administered, e.g., a wetting agent.

In an aspect, the subject is less than 150 kilograms, 100 kilograms, less than 50 kilograms, less than 25 kilograms, or less than 10 kilograms. In this or other aspects, the subject may be less than 12 or 13 years old. In this or other aspects, the subject could be classified as human, male or female. In this or other aspects, the subject may be an agricultural animal. In this or other aspects, the subject may be non-human.

The viscosity of the medicament to be administered can vary. Viscosity of a medicament formulation can be measured by using a viscometer. In various aspects, viscosity of a medicament at 25° C. ranges from about 0.3 to about 300 cP, from about 0.3 to about 200 cP, from about 0.3 to about 100 cP, from about 0.3 to about 50 cP, from about 0.3 to about 40 cP, from about 0.3 to about 30 cP, from about 0.3 to about 20 cP, from about 0.3 to about 10 cP, from about 0.3 to about 5 cP, from about 0.3 to about 2 cP, from about 0.3 to about 1.5 cP, from about 0.3 to about 1 cP, from about 0.3 to about 0.9 cP, from about 0.3 to about 0.8 cP, from about 0.3 to about 0.7 cP, from about 0.3 to about 0.6 cP, from about 0.3 to about 0.5 cP, or from about 0.3 to about 0.4 cP. In various other aspects, viscosity of a medicament to be administered is about 0.4 to about 1.4 cP, about 0.5 to about 1.3 cP, about 0.6 to about 1.2 cP, about 0.7 to about 1.1 cP, or about 0.8 to about 1.0 cP at room 25° C. In various other aspects, viscosity of a medicament at 25° C. is about 0.3 cP, about 0.4 cP, about 0.5 cP, about 0.6 cP, about 0.7 cP, about 0.8 cP, about 0.9 cP, about 1 cP, about 1.1 cP, about 1.2 cP, about 1.3 cP, about 1.4 cP, or about 1.5 cP.

In some aspects, the active agents may exhibit increased stability and/or solubility at acid or alkaline pH and may be centrally administered in such form. In other aspects, a physiologically suitable pH (e.g., in the range of about pH 6.8-8.2,

depending on the part of the eye) may be preferred for ophthalmic administration. However, titration to physiological pH may result in solubility and/or stability issues for many active agents. Therefore, it may be preferred in some cases to develop aqueous formulations in which the active agent is formulated with a solubility-enhancing agent or stabilizing excipients at a physiologically suitable pH. If titration is desired, any suitable buffer known in the medicament arts may be used (e.g., phosphate, acetate, glycine, citrate, imidazole, TRIS, MES, MOPS).

Further it may be desirable to maintain physiological isotonicity. For instance, in certain aspects, an osmolality ranging from about 100 to about 1000 mmol/kg, more particularly from about 280 to about 320 mmol/kg may be desired. Any suitable manner of adjusting tonicity known in the pharmaceutical arts may be used, e.g., adjustment with NaCl.

In accordance with certain aspects of the invention, medicament compositions are designed to maximize solubility and stability in ophthalmic applications and under conditions of use for administration to the eye.

#### 1. Solubility Enhancing Agents

Again, in accordance with certain aspects of the invention, formulation active agents in aqueous solutions at physiological pH and tonicity are undertaken. However, to provide adequate solubility to the composition, the use of solubility enhancing agents may optionally be required.

Without intending to be limited by theory, in certain aspects, solubility enhancing agents may utilize their amphiphilic characteristics to increase the solubility of active agents in water. As generally understood by those skilled in the art, a wide variety of solubility enhancing agents that possess both nonpolar and hydrophilic moieties may be employed in connection with the present invention. However, amphiphilic agents possessing stronger hydrophobic character have the potential to interact with cell membranes and produce toxic effects. Therefore, again, without intending to be limited by theory, solubility enhancing agents with minimal hydrophobic character may be preferred in certain aspects within the context of the present invention, as such agents will be well-tolerated.

In addition to minimizing the hydrophobic character of the solubilizing agents employed, toxicity during administration may be reduced if the solubility enhancing agent is readily degraded in a cellular environment. The ability of cells to degrade compounds prevents their accumulation during chronic administration. To this end, the solubility enhancing agents may optionally include chemically-labile ester and ether linkages that contribute to low toxicity, and thereby prevent significant cellular accumulations during chronic administration.

In this regard, in accordance with certain aspects of the invention, the solubility-enhancing agent includes those that can be selected from cyclodextrins, e.g.,  $\beta$ -hydroxypropyl-cyclodextrin, sulfobutyl-ether- $\beta$  cyclodextrin, etc.

In other aspects, the solubility-enhancing agent may be selected from sucrose esters. Such agents are formed of two benign components (sucrose and fatty acids) linked by a highly labile ester bond. Although a readily-degradable linkage is beneficial from a toxicity standpoint, the solubility enhancing agent must be sufficiently robust to maintain its ability to solubilize the active agent during the desired conditions of use.

Generally, certain compositions of the invention may be prepared by formulating the desired amount, which may be a therapeutically-effective amount, of the desired active agent in a suitable solubility enhancing agent. Solubility enhancing agents include, but are not limited to, e.g., cyclodextrins,

octylglucoside, pluronic F-68, Tween 20, sucrose esters, glycerol, ethylene glycol, alcohols, propylene glycol, carboxy methyl cellulose, solutol, mixtures thereof, etc. Other solubility-enhancing agents include, but are not limited to, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), arginine, proline, betaine, polyamino acids, peptides, nucleotides, sorbitol, sodium dodecylsulphate (SDS), sugar esters, other surfactants, other detergents and pluronics, and mixtures thereof. Alternatively, stable multiphase systems could be employed to safely solubilize therapeutics for intrathecal delivery (e.g., liposomes, micro/nano emulsions, nanoparticles, dendrimers, micro/nano spheres).

Any suitable amount of solubility enhancing agent sufficient to solubilize the active agent of interest to the desired concentration may be used. In certain aspects, molar ratios of active agent to solubility-enhancing agent ranging from about 0.5:1 to about 1:10, particularly, about 1:1 to about 1:5, more particularly 1:1 to about 1:2, may be used to achieve adequate solubility of the active agent to the desired concentrations.

#### 2. Stabilizing Excipients

In addition to solubility, the active agent must be sufficiently stable within the composition to withstand hydrolytic and oxidative degradation in order to maintain biological activity during administration. Active agents generally possess the therapeutic effects observed during conventional administration; the stability of the medicament in the composition prior to central administration is also of importance. To this end, in certain aspects, the compositions of the present invention may further include stabilizing excipients and buffers acceptable for use in the eye.

Considering that oxidation represents a common degradation pathway, in certain aspects, the compositions of the invention may be deoxygenated (e.g., by saturating with nitrogen gas) to minimize the formation of reactive oxygen species that would degrade the active agent during storage. Another method would be to ensure that formulations are stored in a container that does not allow passage of light, thereby minimizing photo-induced degradation. In addition, in accordance with certain aspects of the invention, stabilizing excipients may optionally be used to, e.g., prevent or slow degradation by oxidation and/or hydrolysis of the active agents. For example, vitamin E, methionine, chelators and mannitol may be used to reduce oxidative degradation. Since the rates of many degradation reactions are pH-dependent, such formulations may include any suitable buffering agent known in the art (e.g., phosphate, acetate, glycine, citrate, imidazole, TRIS, MES, MOPS).

Stabilizing excipients useful in the context of the compositions described herein include any medicamentally acceptable components which function to enhance the physical stability, and/or chemical stability of the active agent in the compositions of the invention. The medicament compositions described herein may include one or more stabilizing excipients, and each excipient may have one or more stabilizing functions.

In one aspect, the stabilizing excipient may function to stabilize the active agent against chemical degradation, e.g., oxidation, deamidation, deamination, or hydrolysis. In this regard, the stabilizing excipients may optionally be selected from antioxidants, such as ascorbic acid (vitamin C), vitamin E, tocopherol conjugates, tocopherol succinate, PEGylated tocopherol succinate, Tris salt of tocopherol succinate, Trolox, mannitol, sucrose, phytic acid, trimercaprol or glutathione.

The term "effective amount" refers to an amount of an active agent used to treat, ameliorate, prevent, or eliminate the identified ophthalmic condition (e.g., disease or disorder), or

## 11

to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers, antigen levels, or time to a measurable event, such as morbidity or mortality. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. Any of the agents can be provided in an effective amount.

For any active agent, the effective amount can be estimated initially either in cell culture assays, e.g., in animal models, such as rat or mouse models. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

To assist in understanding the present invention, the following Example is included. The experiments described herein should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.

U.S. Application Attorney Docket Number 24591.003-US03, filed concurrently herewith, entitled "Drop-Generat-

## 12

ing Device" and U.S. Application Attorney Docket Number 24591.003-US02, filed concurrently herewith, entitled "Method and System for Performing Remote Treatment and Monitoring" are also each herein incorporated by reference in their entireties.

## EXAMPLE

Table A describes quantification of average droplet size and the maximum number of doses of various medications from individual eyedropper containers. Each experiment is repeated in three trials to calculate a more accurate average droplet size. By taking the volume of individual bottles and dividing it by the average droplet size, the maximum number of doses per eyedropper is calculated.

Column A contains the retail name of medications. In column B, the concentration of active ingredient of medication is listed as a percentage where publically available. Column C contains the name of preservative used in the medication, with column D displaying the percentage of the preservative in the solution. Column E is the manufacturer of the medication and column F is its classification as over-the counter (OTC) or by prescription (Rx). Columns G, H and I represent values from individual trials. The average in Column J is calculated using the values of G, H and I. Every bottle has a unique volume to contain a set amount of medication, which is noted in column K. The value in column K is divided by the average in column J to determine the number of doses possible as noted in Column L.

TABLE A

Name	med in solution (%)	Preservative	Preserv in solution (%)	Company	RX/ OTC	Trial 1	Trial 2	Trial 3	Avg	Bottle Size (ml)	Doses
Blink tears		Sodium Chlorate		Advanced Medical Optics	OTC	0.041	0.046	0.041	0.0427	15	352
thera tears (sodium carboxymethylcellulose)	0.025	Sodium Perborate		Advanced Vision Research	OTC	0.046	0.05	0.049	0.0483	30	621
Naphcon A (Pheniramine Maleate)	0.3	Benzalkonium Chloride	0.01	Alcon	OTC	0.038	0.04	0.04	0.0393	15	381
Opti-free express rewetting drops		Polyquad		Alcon	OTC	0.036	0.038	0.038	0.037333	20	535.7
Opti-free Replenish		Polyquad	0.001	Alcon	OTC	0.026	0.027	0.029	0.0273	10	366
Systane Balance (propylene glycol)	0.6	Polyquad	0.001	Alcon	OTC	0.039	0.035	0.035	0.0363	10	275
Systane Lubricant Eye drops		Polyquad		Alcon	OTC	0.038	0.044	0.05	0.0440	15	341
Systane ultra		Polyquad	0.001	Alcon	OTC	0.047	0.047	0.049	0.0477	10	210
Tears Naturale II		Polyquad	0.001	Alcon	OTC	0.057	0.056	0.06	0.0577	15	260
Refresh optive (Carboxymethylcellulose Sodium)	0.5	PURITE		Allergan	OTC	0.04	0.041	0.04	0.0403	15	372
Refresh Tears (Carboxymethylcellulose Sodium)	0.5	PURITE		Allergan	OTC	0.054	0.055	0.059	0.0560	15	268
Adv. Eye Relief Dry Eye		Benzalkonium Chloride	0.01	Bausch & Lomb	OTC	0.027	0.028	0.03	0.0283	15	529
Adv. Eye relief Redness (Naphazoline HCl)	0.03	Benzalkonium Chloride	0.01	Bausch & Lomb	OTC	0.032	0.031	0.032	0.0317	15	474
Alaway (ketotifen fumarate)	0.035	Benzalkonium Chloride	0.01	Bausch & Lomb	OTC	0.036	0.034	0.035	0.0350	10	286
Muro128				Bausch & Lomb	OTC	0.038	0.041	0.038	0.0390	15	385
Opcon-A		Benzalkonium Chloride		Bausch & Lomb	OTC	0.028	0.031	0.032	0.0303	15	495
Remu		Sorbic acid, Disodium edetate	0.15 and .1	Bausch & Lomb	OTC	0.036	0.039	0.041	0.0387	15	388

TABLE A-continued

Name	med in solution (%)	Preservative	Preserv in solution (%)	Company	RX/ OTC	Trial 1	Trial 2	Trial 3	Avg	Bottle Size (ml)	Doses
Sensitive eyes		Sorbic Acid and Disodium edetate	.1 and .025	Bausch & Lomb	OTC	0.039	0.038	0.04	0.0390	30	769
Soothe xp		polyhexa-methylene biguanide		Bausch & Lomb	OTC	0.033	0.033	0.033	0.0330	15	455
Visine A.C. (Tetrahydrozoline HCl)	0.05	Benzalkonium Chloride		Johnson & Johnson	OTC	0.036	0.036	0.038	0.0367	15	409
Visine Advanced Relief (Tetrahydrozoline HCl)	0.05	Benzalkonium Chloride		Johnson & Johnson	OTC	0.038	0.043	0.041	0.0407	19	467
Visine Dry eye relief		Benzalkonium Chloride	0.01	Johnson & Johnson	OTC	0.031	0.03	0.027	0.0293	15	511
Visine L.R. Long Lasting Redness Relief (Oxymetazoline HCl)	0.025	Benzalkonium Chloride		Johnson & Johnson	OTC	0.036	0.036	0.032	0.0347	15	433
Visine Max Redness Relief (Tetrahydrozoline HCl)	0.05	Benzalkonium Chloride		Johnson & Johnson	OTC	0.04	0.042	0.042	0.0413	15	363
Visine original (Tetrahydrozoline HCl)	0.05	Benzalkonium Chloride		Johnson & Johnson	OTC	0.034	0.034	0.034	0.0340	19	559
Visine-A (Pheniramine Maleate)	0.3	Benzalkonium Chloride	0.01	Johnson & Johnson	OTC	0.031	0.031	0.033	0.0317	15	474
Optimum WRW (fluorosilicone acrylate)		Benzyl Alcohol, Sorbic Acid, Disodium edetate	.1, .05, .1	Lobob	OTC	0.055	0.052	0.058	0.055	30	545.5
Clear eyes natural tears lubricant		Benzalkonium Chloride		MedTech Products	OTC	0.026	0.03	0.024	0.0267	15	563
Clear eyes Redness relief (naphazoline HCl)	0.012	Benzalkonium Chloride		MedTech Products	OTC	0.024	0.02	0.021	0.0217	30	1385
GenTeal (hydroxypropyl methylcellulose)		GenAqua (Sodium perborate)		Novartis	OTC	0.046	0.046	0.047	0.0463	15	324
Hypo tears		Benzalkonium Chloride	0.01	Novartis	OTC	0.032	0.039	0.038	0.0363	30	826
Zaditor (ketotifen fumarate)	0.025	Benzalkonium Chloride	0.01	Novartis	OTC	0.033	0.032	0.034	0.0330	5	152
Rohto arctic (Tetrahydrozoline HCl)	0.05			Rohto	OTC	0.035	0.03	0.034	0.0330	13	394
Rohto Cool (naphazoline HCl)	0.012	Benzalkonium Chloride		Rohto	OTC	0.037	0.033	0.03	0.0333	13	390
Rohto Hydra (hypromellose)	0.3			Rohto	OTC	0.041	0.034	0.03	0.0350	13	371
Rohto ice (Zinc Sulfate)	0.25			Rohto	OTC	0.035	0.03	0.038	0.0343	13	379
Similasan allergy eye relief		Silver sulphate		Similasan	OTC	0.044	0.044	0.046	0.0447	10	224
Similasan pink eye relief		Silver sulphate		Similasan	OTC	0.048	0.045	0.048	0.0470	10	213
Walgreens artificial tears		Benzalkonium Chloride	0.01	Walgreens	OTC	0.028	0.03	0.032	0.0300	30	1000
Walgreens sterile artificial tears (ampules)		None	0	Walgreens	OTC	0.031	0.033	0.036	0.0333		32
AK-Dilate Phenylephrine Hydrochloride	2.5	Benzalkonium Chloride	0.01	Akon	Rx	0.023	0.029	0.029	0.0270	15	556
Azopt (brinzolamide)	1	Benzalkonium Chloride	0.01	Alcon	Rx	0.039	0.039	0.039	0.0390	10	256
Nevanac (nepafenac)	0.1	Benzalkonium Chloride	0.005	Alcon	Rx	0.04	0.039	0.043	0.0407	3	74
Pataday (olopatadine hydrochloride)	0.2	Benzalkonium Chloride	0.01	Alcon	Rx	0.028	0.029	0.027	0.0280	2.5	89
Travatan Z(travoprost)	0.004	Sofzia		Alcon	Rx	0.03	0.034	0.034	0.0327	5	153
vigamox (moxifloxacin hydrochloride)	0.5	None	0	Alcon	Rx	0.039	0.045	0.046	0.0433	3	69

TABLE A-continued

Name	med in solution (%)	Preservative	Preserv in solution (%)	Company	RX/ OTC	Trial 1	Trial 2	Trial 3	Avg	Bottle Size (ml)	Doses
Ketorolac	0.4	Benzalkonium Chloride	0.006	Alcon-Falcon	Rx	0.025	0.026	0.024	0.0250	5	200
Tromethamine Prednisolone Acetate Ophthalmic suspension	1	Benzalkonium Chloride	0.01	Alcon-Falcon	Rx	0.03	0.033	0.037	0.0333	5	150
Proparacaine Hydrochloride	0.5	Benzalkonium Chloride	0.01	Alcon-Falcon	Rx	0.036	0.04	0.042	0.0393	15	381
Ophthalmic solution Tobramycin and Dexamethasone	0.4	Benzalkonium Chloride	0.01	Alcon-Falcon	Rx	0.032	0.033	0.029	0.0313	5	160
Tropicamide	1	Benzalkonium Chloride	0.01	Alcon-Falcon	Rx	0.033	0.028	0.034	0.0317	15	474
Alphagan P (brimonidine tartrate)	0.1	PURITE	0.005	Allergan	Rx	0.041	0.042	0.05	0.0443	5	113
Lumigan (bimatoprost)	0.03	Benzalkonium Chloride	0.005	Allergan	Rx	0.025	0.021	0.022	0.0227	5	221
Restasis (cyclosporine) (ampules)	0.05	None (Sterile)	0	Allergan	Rx	0.025	0.023	0.025	0.0243		30
Zymar (gatifloxacin)	0.3	Benzalkonium Chloride	0.005	Allergan	Rx	0.029	0.031	0.031	0.0303	5	165
Zymaxid (gatifloxacin)	0.5	Benzalkonium Chloride	0.005	Allergan	Rx	0.033	0.035	0.032	0.0333	2.5	75
Alrex (loteprednol etabonate)	0.2	Benzalkonium Chloride	0.01	Bausch & Lomb	Rx	0.032	0.034	0.033	0.0330	5	152
Bepreve (bepotastine besilate)	1.5	Benzalkonium Chloride	0.005	Bausch & Lomb	Rx	0.031	0.033	0.03	0.0313	5	160
Besivance (besifloxacin)	0.6	Benzalkonium Chloride	0.01	Bausch & Lomb	Rx	0.036	0.041	0.04	0.0390	5	128
Lotemax (loteprednol etabonate)	0.5	Benzalkonium Chloride	0.01	Bausch & Lomb	Rx	0.029	0.031	0.031	0.0303	5	165
Dorzolamide HCl		Benzalkonium Chloride	0.0075	Hi-tech	Rx	0.051	0.048	0.053	0.0507	10	197
Timolol Maleate		Benzalkonium Chloride	0.003	Inspire	Rx	0.046	0.045	0.051	0.0473	2.5	53
AzaSite (azithromycin)	1	Benzalkonium Chloride		Ista	Rx	0.046	0.04	0.038	0.0413	1.7	41
Bromday (bromfenac)	0.09	Benzalkonium Chloride		Pack	Rx	0.028	0.027	0.025	0.0267	5	188
Levofloxacin	0.5	Benzalkonium Chloride	0.005	Pfizer	Rx	0.022	0.023	0.026	0.0237	2.5	106
Xalatan (latanoprost)	0.005	Benzalkonium Chloride	0.02	Senju	Rx	0.026	0.031	0.031	0.0293	5	170
Istalol	0.5	Benzalkonium Chloride	0.005	Sirion Therapeutics	Rx	0.04	0.039	0.034	0.0377	5	133
Durezol (difluprednate)	0.05	Sorbic Acid	0.1	Teva	Rx	0.036	0.04	0.04	0.0387	10	259
Dorzolamide HCl	2	Benzalkonium Chloride	0.0075			0.035	0.033	0.034	0.0340		
BAK free Latanoprost											

What is claimed:

1. A method of delivering a medicament to an eye of a subject in need thereof as an ejected stream of droplets, the method comprising:

(a) generating the ejected stream of droplets containing said medicament via a piezoelectric actuated ejection device, said ejector device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezo electric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation;

wherein said ejected droplets have an average droplet ejecting size of between about 20 microns to about 100

microns in diameter and an average initial droplet ejecting velocity between 1 m/s and 10 m/s; and

(b) delivering said ejected stream of droplets containing said medicament to said eye of the subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye.

2. The method according to claim 1, wherein said medicament is delivered in an aqueous droplet solution.

3. The method according to claim 2, wherein said medicament is delivered in an oil/water emulsion droplet.

4. The method according to claim 3, wherein said oil in said oil/water emulsion droplet is a glycerin, a castor oil, or a polysorbate 80 mixture.

5. The method according to claim 1, wherein said medicament is a glaucoma medicament.

6. The method according to claim 1, wherein said medicament is an antibiotic.

17

7. The method according to claim 1, wherein said average droplet ejecting size is between about 30 microns to about 60 microns.

8. The method according to claim 1, wherein said average initial droplet ejecting velocity is between about 1 m/s to about 4 m/s.

9. The method according to claim 1, wherein said medicament is selected from the group consisting of ranibizumab antibody FAB, VEGF Trap fusion molecule, microplasmin enzyme, macugen pegylated polypeptide, and bevacizumab.

10. The method according to claim 1, wherein said medicament comprises a medicament selected from the group consisting of carboxymethylcellulose sodium, tetrahydrozoline HCl, pheniramine maleate, ketotifen fumarate, oxymetazoline HCl, naphazoline HCl, pheniramine maleate, moxifloxacin hydrochloride, bromfenac, proparacaine hydrochloride, difluprednate, gatifloxacin, travoprost, bimatoprost, bimatoprost and BAK free latanoprost.

11. The method according to claim 1, wherein said medicament comprises a medicament selected from the group consisting of fluorosilicone acrylate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, tetrahydrozoline HCl, carboxymethylcellulose sodium, propylene glycol, hypromellose, zinc sulfate, dorzolamide HCl timolol maleate, azithromycin, brimonidine tartrate, nepafenac, brinzolamide, besifloxacin, dorzolamide HCl, prenisone acetate, loteprednol etabonate, tobramycin/dexamethasone, and cyclosporine.

12. The method according to claim 1, wherein said medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzolamide HCl, and BAK free latanoprost.

13. A method for providing a solution as an ejected stream of droplets to an eye of a subject in need thereof, the method comprising:

(a) generating an ejected stream of droplets of said solution via a piezoelectric actuated ejection device, the ejection device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezoelectric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation;

wherein said ejected droplets have an average droplet ejecting size of between about 20 microns to about 100 microns in diameter and an average initial droplet ejecting velocity of between about 1 m/s and 10 m/s; and  
(b) delivering said ejected stream of droplets of said solution to said eye of a subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye.

14. The method of claim 13, wherein said solution is an isotonic saline solution.

15. The method according to claim 13, wherein said solution comprises a medicament and said medicament is delivered in an aqueous droplet solution.

16. The method according to claim 13, wherein said solution comprises a medicament and said medicament is delivered in an oil/water emulsion droplet.

18

17. The method according to claim 16, wherein said oil in said oil/water emulsion droplet is a glycerin, a castor oil, or a polysorbate 80 mixture.

18. The method according to claim 15, wherein said medicament is a glaucoma medicament.

19. The method according to claim 15, wherein said medicament is an antibiotic.

20. The method according to claim 13, wherein said average droplet ejecting size is between about 30 microns to about 60 microns.

21. The method according to claim 13, wherein said average droplet initial ejecting velocity is between about 1 m/s to about 4 m/s.

22. The method according to claim 15, said medicament is selected from the group consisting of ranibizumab antibody FAB, VEGF Trap fusion molecule, microplasmin enzyme, macugen pegylated polypeptide, and bevacizumab.

23. The method according to claim 15, wherein said medicament comprises a medicament selected from the group consisting of carboxymethylcellulose sodium, tetrahydrozoline HCl, pheniramine maleate, ketotifen fumarate, oxymetazoline HCl, naphazoline HCl, pheniramine maleate, moxifloxacin hydrochloride, bromfenac, proparacaine hydrochloride, difluprednate, gatifloxacin, travoprost, bimatoprost, bimatoprost and BAK free latanoprost.

24. The method according to claim 15, wherein said medicament comprises a medicament selected from the group consisting of fluorosilicone acrylate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, tetrahydrozoline HCl, carboxymethylcellulose sodium, propylene glycol, hypromellose, zinc sulfate, dorzolamide HCl timolol maleate, azithromycin, brimonidine tartrate, nepafenac, brinzolamide, besifloxacin, dorzolamide HCl, prenisone acetate, loteprednol etabonate, tobramycin/dexamethasone, and cyclosporine.

25. The method according to claim 15, wherein said medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzolamide HCl, and BAK free latanoprost.

26. A method of treating glaucoma in a subject in need thereof comprising:

(a) generating an ejecting stream of droplets containing a medicament for treatment of glaucoma via a piezoelectric actuated ejection device, the ejection device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including a plurality of openings formed through its thickness; and a piezoelectric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation;

wherein said droplets have an average droplet ejecting size of between about 20 microns to about 100 microns in diameter and an average initial droplet ejecting velocity of between about 1 m/s and 10 m/s; and

(b) delivering said ejected stream of droplets containing said medicament to an eye of said subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye.

19

27. The method according to claim 26, wherein said medicament is delivered in an aqueous droplet solution.

28. The method according to claim 27, wherein said medicament is delivered in an oil/water emulsion droplet.

29. The method according to claim 28, wherein said oil in said oil/water emulsion droplet is a glycerin, a castor oil, or a polysorbate 80 mixture.

30. The method according to claim 26, wherein said average droplets ejecting size is between about 30 microns to about 60 microns.

31. The method according to claim 26, wherein said average droplet initial ejecting velocity is between about 1 m/s to about 4 m/s.

32. The method according to claim 26, said medicament is selected from the group consisting of travoprost, timolol ophthalmic, latanoprost, bimatoprost, dorzolamide HCl timolol maleate, brimonidine tartrate, brinzolamide, dorzolamide HCl, and BAK free latanoprost.

33. A method of providing a reduced dosage of a medicament to an eye of a subject in need thereof as an ejected stream of droplets, the method comprising:

(a) generating an ejected stream of droplets containing said medicament via a piezoelectric actuated ejection device, the ejection device comprising: a housing; a reservoir disposed within the housing for receiving a volume of ophthalmic fluid; an ejector mechanism comprising an ejector plate having a first surface coupled to a fluid delivery area of the reservoir, the ejector plate including

20

a plurality of openings formed through its thickness; and a piezoelectric actuator coupled to a second surface of the ejector plate, the actuator being operable to oscillate the ejector plate at a frequency to thereby generate the ejected stream of droplets upon actuation;

wherein said droplets have an average ejecting droplet size of between about 20 microns and about 100 microns in diameter and an average initial droplet ejecting velocity of between 1 m/s and 10 m/s; and

(b) delivering said ejected stream of droplets containing said medicament to said eye of said subject in need thereof, wherein between about 85% to about 100% of the ejected mass of said droplets are deposited on the eye, and wherein said droplets provide a total volume of less than 30  $\mu$ l to said eye.

34. The method of claim 1, wherein said medicament has a viscosity at 25° C. is about 0.3 centipoise (cP) to about 300 cP.

35. The method of claim 34, wherein said viscosity is about 0.3 cP to about 30 cP.

36. The method of claim 1, wherein said medicament is isotonic with human tears or eye tissue.

37. The method of claim 1, wherein said medicament has an osmolality ranging from about 100 milli-osmoles/kilogram (mmol/kg) to about 1000 mmol/kg.

38. The method of claim 37, wherein said medicament has an osmolality ranging from about 280 mmol/kg to about 320 mmol/kg.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**


PATENT NO. : 9,087,145 B2  
APPLICATION NO. : 13/184446  
DATED : July 21, 2015  
INVENTOR(S) : Ballou, Jr. et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On Title page, column 1, item 75 under Inventors, line 4, delete "Tsontcho Inachulev," and insert -- Tsontcho Ianchulev, --, therefor.

Signed and Sealed this  
First Day of December, 2015

A handwritten signature in black ink, reading "Michelle K. Lee". The signature is fluid and cursive, with the first letters of each name being capitalized and prominent.

Michelle K. Lee  
*Director of the United States Patent and Trademark Office*